Rosenquist and colleagues reported a comparable poor outcome in patients with SF3B1 and TP53 mutations [60], and Wang and colleagues suggested that SF3B1 status could represent an independent risk factor for CLL [56]. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.